| 1 |
35472391 | Rates of In-Hospital Decongestion and Association with Mortality and Cardiovascular Outcomes Among Patients Admitted for Acute Heart Failure. | 2022 Apr 25 |
1 |
| 2 |
34234441 | Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease. | 2021 |
1 |
| 3 |
34514204 | Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD. | 2021 Sep |
1 |
| 4 |
34719623 | Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. | 2021 |
2 |
| 5 |
32232055 | Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients. | 2020 Jan-Apr |
1 |
| 6 |
32535124 | Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure. | 2020 Jul |
1 |
| 7 |
32543020 | Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF). | 2020 Aug |
1 |
| 8 |
32683063 | Pharmacological Dilutional Therapy Using the Vasopressin Antagonist Tolvaptan for Young Patients With Cystinuria: A Pilot Investigation. | 2020 Oct |
1 |
| 9 |
32734225 | Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan. | 2020 Jan-Feb |
1 |
| 10 |
32734960 | Erratum Regarding "Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan" (Kid Med. 2020;2(1):20-28). | 2020 Mar-Apr |
1 |
| 11 |
32995715 | Assessing Splanchnic Compartment Using Portal Venous Doppler and Impact of Adding It to the EVEREST Score for Risk Assessment in Heart Failure. | 2020 Sep |
1 |
| 12 |
30637666 | Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases. | 2019 May |
1 |
| 13 |
30733892 | Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma. | 2019 |
1 |
| 14 |
30774351 | New therapies for the treatment of heart failure: a summary of recent accomplishments. | 2019 |
1 |
| 15 |
30802995 | Tolvaptan for Volume Management in Heart Failure. | 2019 Apr |
1 |
| 16 |
30898339 | Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. | 2019 Jul |
4 |
| 17 |
31039325 | ADPKD-what the radiologist should know. | 2019 Jun |
1 |
| 18 |
29629516 | Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone. | 2018 Apr 9 |
1 |
| 19 |
29801549 | Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High? | 2018 Jun |
1 |
| 20 |
30303493 | An update on tolvaptan for autosomal dominant polycystic kidney disease. | 2018 Sep |
1 |
| 21 |
30364227 | Hyponatremia: An Unusual Presentation in a Neonate With Chromosome 1q21.1 Deletion Syndrome. | 2018 |
1 |
| 22 |
28288570 | Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects. | 2017 Mar 13 |
1 |
| 23 |
28302292 | Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. | 2017 Mar 21 |
1 |
| 24 |
28326667 | The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment. | 2017 Sep |
1 |
| 25 |
28810844 | Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. | 2017 Aug 15 |
1 |
| 26 |
28905441 | The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives. | 2017 Oct |
1 |
| 27 |
26610908 | Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. | 2016 Jun |
2 |
| 28 |
26742474 | Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). | 2016 Feb 15 |
1 |
| 29 |
26742881 | Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure. | 2016 |
1 |
| 30 |
26784173 | Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure. | 2016 Jan 14 |
2 |
| 31 |
27357439 | Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin. | 2016 Jul 27 |
2 |
| 32 |
27628415 | Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders. | 2016 Sep 28 |
2 |
| 33 |
27921039 | Clinical Manifestation and Management of ADPKD in Western Countries. | 2016 Oct |
1 |
| 34 |
30547521 | [Vasopressin antagonist (Tolvaptan)]. | 2016 Aug |
1 |
| 35 |
25728846 | Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). | 2015 Mar 15 |
1 |
| 36 |
26126090 | Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease? | 2015 Jul |
1 |
| 37 |
26374918 | Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. | 2015 Sep |
1 |
| 38 |
26405324 | Experience with Tolvaptan for Euvolemic and Hypervolemic Hyponatremia in the Acute Care Setting. | 2015 May |
1 |
| 39 |
26714385 | The Vasopressin 2 Receptor Antagonist Tolvaptan Improves Nutrition and Inflammatory States in Peritoneal Dialysis Patients with Diabetes Mellitus. | 2015 |
1 |
| 40 |
26885186 | Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials. | 2015 |
1 |
| 41 |
24511399 | Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans. | 2014 |
1 |
| 42 |
24949180 | Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India. | 2014 Jan |
1 |
| 43 |
24954239 | Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. | 2014 |
1 |
| 44 |
24965902 | Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects. | 2014 Jun 25 |
1 |
| 45 |
25268207 | [Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan]. | 2014 Oct |
1 |
| 46 |
26237603 | Review of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions. | 2014 Nov 12 |
1 |
| 47 |
23059198 | Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. | 2013 Feb |
1 |
| 48 |
23206923 | Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). | 2013 Feb 15 |
1 |
| 49 |
23239836 | Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. | 2013 Jan |
3 |
| 50 |
23351825 | Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. | 2013 Feb |
1 |